Sökning: L773:1528 0020 >
Five-year follow-up...
Five-year follow-up of KEYNOTE-087 : pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
-
- Armand, Philippe (författare)
- Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.;Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
-
- Zinzani, Pier Luigi (författare)
- Azienda Osped Univ Bologna, Ist Ricovero & Cura Carattere Sci, Ist Ematol Seragnoli, Bologna, Italy.;Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy.
-
- Lee, Hun Ju (författare)
- Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA.
-
visa fler...
-
- Johnson, Nathalie A. (författare)
- Jewish Gen Hosp, Dept Med, Montreal, PQ, Canada.
-
- Brice, Pauline (författare)
- Hop St Louis, Hematooncol, Paris, France.
-
- Radford, John (författare)
- Christie NHS Fdn Trust, Dept Med Oncol, NIHR Clin Res Facil, Manchester, England.;Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, England.
-
- Ribrag, Vincent (författare)
- Gustave Roussy, Early Drug Dev Dept DITEP, Villejuif, France.
-
- Molin, Daniel, 1969- (författare)
- Uppsala universitet,Cancerimmunterapi
-
- Vassilakopoulos, Theodoros P. (författare)
- Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Hematol & Bone Marrow Transplantat, Athens, Greece.
-
- Tomita, Akihiro (författare)
- Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Nagoya, Japan.
-
- von Tresckow, Bastian (författare)
- Univ Cologne, Med Fac, Dept Internal Med 1, Cologne, Germany.;Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Hematol & Stem Cell Transplantat, Essen, Germany.;Univ Cologne, Univ Hosp Cologne, Cologne, Germany.
-
- Shipp, Margaret A. (författare)
- Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
-
- Herrera, Alex F. (författare)
- City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA USA.
-
- Lin, Jianxin (författare)
- Merck & Co Inc, Dept Med Oncol, Rahway, NJ USA.
-
- Kim, Eunhee (författare)
- Merck & Co Inc, Dept Med Oncol, Rahway, NJ USA.
-
- Chakraborty, Samhita (författare)
- Merck & Co Inc, Dept Med Oncol, Rahway, NJ USA.
-
- Marinello, Patricia (författare)
- Merck & Co Inc, Dept Med Oncol, Rahway, NJ USA.
-
- Moskowitz, Craig H. (författare)
- Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med, Miami, FL USA.
-
visa färre...
-
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA;Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. Azienda Osped Univ Bologna, Ist Ricovero & Cura Carattere Sci, Ist Ematol Seragnoli, Bologna, Italy.;Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy. (creator_code:org_t)
- American Society of Hematology, 2023
- 2023
- Engelska.
-
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 142:10, s. 878-886
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activity with acceptable safety in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). However, long-term response durability and outcome of patients who receive a second course after treatment discontinuation after complete response (CR) remain of clinical interest. We present KEYNOTE-087 data after >5 years of median follow-up. Patients with R/R cHL and progressive disease (PD) after autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV; cohort 1), salvage chemotherapy and BV without ASCT (cohort 2), or ASCT without subsequent BV (cohort 3), received pembrolizumab for <= 2 years. Patients in CR who discontinued treatment and subsequently experienced PD were eligible for second-course pembrolizumab. Primary end points were the objective response rate (ORR) using blinded central review and safety. The median follow-up was 63.7 months. ORR was 71.4% (95% confidence interval [CI], 64.8-77.4; CR, 27.6%; partial response, 43.8%). Median duration of response (DOR) was 16.6 months; median progression-free survival was 13.7 months. A quarter of responders, including half of complete responders, maintained a response for >= 4 years. Median overall survival was not achieved. Among 20 patients receiving second-course pembrolizumab, ORR for 19 evaluable patients was 73.7% (95% CI, 48.8-90.8); median DOR was 15.2 months. Any-grade treatment-related adverse events occurred in 72.9% of patients and grade 3 or 4 adverse events occurred in 12.9% of patients; no treatment-related deaths occurred. Single-agent pembrolizumab can induce durable responses, particularly in patients achieving CR. Second-course pembrolizumab frequently reinduced sustained responses after relapse from initial CR.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Blood
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Armand, Philippe
-
Zinzani, Pier Lu ...
-
Lee, Hun Ju
-
Johnson, Nathali ...
-
Brice, Pauline
-
Radford, John
-
visa fler...
-
Ribrag, Vincent
-
Molin, Daniel, 1 ...
-
Vassilakopoulos, ...
-
Tomita, Akihiro
-
von Tresckow, Ba ...
-
Shipp, Margaret ...
-
Herrera, Alex F.
-
Lin, Jianxin
-
Kim, Eunhee
-
Chakraborty, Sam ...
-
Marinello, Patri ...
-
Moskowitz, Craig ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Blood
- Av lärosätet
-
Uppsala universitet